QURE vs. MACK, PRLD, OVID, ACRV, GALT, OGI, TRVI, CDT, ZVRA, and DSGN
Should you be buying uniQure stock or one of its competitors? The main competitors of uniQure include Merrimack Pharmaceuticals (MACK), Prelude Therapeutics (PRLD), Ovid Therapeutics (OVID), Acrivon Therapeutics (ACRV), Galectin Therapeutics (GALT), Organigram (OGI), Trevi Therapeutics (TRVI), Conduit Pharmaceuticals (CDT), Zevra Therapeutics (ZVRA), and Design Therapeutics (DSGN). These companies are all part of the "pharmaceutical preparations" industry.
uniQure (NASDAQ:QURE) and Merrimack Pharmaceuticals (NASDAQ:MACK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings.
In the previous week, uniQure and uniQure both had 1 articles in the media. uniQure's average media sentiment score of 0.00 equaled Merrimack Pharmaceuticals'average media sentiment score.
uniQure presently has a consensus price target of $32.00, indicating a potential upside of 582.30%. Given uniQure's higher probable upside, equities analysts plainly believe uniQure is more favorable than Merrimack Pharmaceuticals.
Merrimack Pharmaceuticals has lower revenue, but higher earnings than uniQure. Merrimack Pharmaceuticals is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.
78.8% of uniQure shares are owned by institutional investors. Comparatively, 64.0% of Merrimack Pharmaceuticals shares are owned by institutional investors. 4.1% of uniQure shares are owned by insiders. Comparatively, 28.9% of Merrimack Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Merrimack Pharmaceuticals has a net margin of 0.00% compared to uniQure's net margin of -1,947.09%. Merrimack Pharmaceuticals' return on equity of -6.24% beat uniQure's return on equity.
uniQure has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Merrimack Pharmaceuticals has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500.
uniQure received 236 more outperform votes than Merrimack Pharmaceuticals when rated by MarketBeat users. Likewise, 70.75% of users gave uniQure an outperform vote while only 67.00% of users gave Merrimack Pharmaceuticals an outperform vote.
Summary
uniQure and Merrimack Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.
Get uniQure News Delivered to You Automatically
Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
